Random dose changes without guidance can lead to weight regain, unpredictable side effects, and wasted medication
[16] [17] Semaglutide (as Wegovy) is further indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with obesity (initial BMI 30 kg/m 2 ) or who are overweight (initial BMI 27 kg/m 2 ) and have at least one weight-related comorbidity such as dysglycemia (prediabetes or type 2 diabetes), hypertension, dyslipidemia, or cardiovascular disease
AMPK signaling in energy control, cartilage biology, and osteoarthritis
Disha Narang, an endocrinologist and director of obesity medicine at Northwestern Medicine, Lake Forest Hospital
Semaglutide with pyridoxine versus tirzepatide with B6 Tirzepatide (the active ingredient in brand-name Mounjaro and Zepbound) is a dual GIP/GLP-1 receptor agonist that has shown even greater weight loss efficacy than semaglutide in head-to-head trials